menu
    • menu

    Company profile for Cognition Therapeutics

    NEW Drugs in Dev: 3
    Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    Contact Supplier

    Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

    Virtual Booth

    Contact Supplier

    Arlanda is your partner for the Brazil market.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Cognition Therapeutics is a privately held biopharmaceutical company focused on the creation and clinical development of a pipeline of disease-modifying small molecule drug candidates that stop neurological disease processes and restore and preserve the building blocks of brain health and function: the synapse. Cognition’s lead candidate, CT1812, is a proprietary first-in-class, orally dosed & highly brain penetrant small mo...
    Cognition Therapeutics is a privately held biopharmaceutical company focused on the creation and clinical development of a pipeline of disease-modifying small molecule drug candidates that stop neurological disease processes and restore and preserve the building blocks of brain health and function: the synapse. Cognition’s lead candidate, CT1812, is a proprietary first-in-class, orally dosed & highly brain penetrant small molecule in development for treatment of mild-to-moderate Alzheimer’s disease. A significant body of genetic and clinical evidence points to accumulation of Aβ as the central pathogenic cause of Alzheimer’s disease.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Cognition TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    2403 Sidney Street Pittsburgh, PA 15203
    Telephone
    Telephone
    412-481-2210
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://cogrx.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    ELCC

    ELCC

    Not Confirmed

    envelop Contact Supplier

    ELCC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Cognition Therapeutics Reports 2025 Results, Clinical Updates
    Cognition Therapeutics Reports 2025 Results, Clinical Updates

    26 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/26/3262885/0/en/Cognition-Therapeutics-Reports-Year-End-2025-Financial-Results-and-Provides-Clinical-Development-Update.html

    GLOBENEWSWIRE
    26 Mar 2026
    Share Share
    Cognition Therapeutics Reports Q4, FY 2025 Financial Results
    Cognition Therapeutics Reports Q4, FY 2025 Financial Results

    23 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/23/3260277/0/en/Cognition-Therapeutics-to-Report-Fourth-Quarter-and-Year-End-2025-Financial-Results.html

    GLOBENEWSWIRE
    23 Mar 2026
    Share Share
    Cognition Advances Zervimesine for Lewy Body Dementia Psychosis
    Cognition Advances Zervimesine for Lewy Body Dementia Psychosis

    02 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/02/3247262/0/en/Cognition-Therapeutics-Advancing-Zervimesine-CT1812-for-Dementia-with-Lewy-Bodies-DLB-Psychosis.html

    GLOBENEWSWIRE
    02 Mar 2026
    Share Share
    Cognition Therapeutics Extends Zervimesine Access Program
    Cognition Therapeutics Extends Zervimesine Access Program

    05 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/05/3232883/0/en/Cognition-Therapeutics-Extends-Expanded-Access-Program-for-Zervimesine-CT1812-in-Dementia-with-Lewy-Bodies.html

    GLOBENEWSWIRE
    05 Feb 2026
    Share Share
    Cognition Therapeutics Wraps FDA Type C Meeting For Zervimesine
    Cognition Therapeutics Wraps FDA Type C Meeting For Zervimesine

    27 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/27/3226367/0/en/Cognition-Therapeutics-Completes-Type-C-Meeting-with-FDA-for-Zervimesine-CT1812-in-Dementia-with-Lewy-Bodies.html

    GLOBENEWSWIRE
    27 Jan 2026
    Share Share
    Cognition Phase 2 Results Show Zervimesine Slows Dementia DLB
    Cognition Phase 2 Results Show Zervimesine Slows Dementia DLB

    06 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/06/3213500/0/en/Cognition-Therapeutics-Publishes-Phase-2-Clinical-Results-Showing-Zervimesine-s-Potential-to-Slow-the-Progression-of-Dementia-with-Lewy-Bodies.html

    GLOBENEWSWIRE
    06 Jan 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search